Enivisia Therapeutics to Present at Glaucoma 360 Conference

Director of Envisia Board to Receive Prestigious Catalyst Award

RESEARCH TRIANGLE PARK, N.C.--()--Envisia Therapeutics today announced that it will present a clinical update at the Glaucoma 360 New Horizons Forum on Friday, February 6, 2015 at the Palace Hotel in San Francisco. The theme of the 4th Annual New Horizons Forum is Speeding the Development of New Therapies and Diagnostics for Glaucoma Patients. The conference, presented by Glaucoma Research Foundation (GRF), provides a forum for unique exchange on research innovation and advances in glaucoma treatment. Globally, glaucoma is a leading cause of preventable blindness.

“We are very proud of the accomplishments we have made to date and to have this opportunity to share the innovative application of our PRINT® technology to the advancement of novel therapeutics in ophthalmology.”

“The theme of this year’s meeting is quite relevant to Envisia given that last year at this time, we had just announced the formation of our company and now this year the initiation of our first clinical trial for ENV515, a promising product candidate for the treatment of glaucoma,” said Ben Yerxa, PhD, Chief Scientific Officer of Envisia. “We are very proud of the accomplishments we have made to date and to have this opportunity to share the innovative application of our PRINT® technology to the advancement of novel therapeutics in ophthalmology.”

ENV515 is an implantable, extended-release formulation of a marketed prostaglandin analogue that has the potential to offer glaucoma patients a therapeutic option that can sustain the reduction of intraocular pressure (IOP) over many months. Envisia uses the power of the proprietary PRINT® (Particle Replication In Non-Wetting Templates) technology to create particle-based ocular therapeutics that can deliver both small and large molecules in multiple formats. Last month, the company announced the initiation of a phase 2a clinical trial to investigate the safety and tolerability of its lead product, ENV515, in patients with glaucoma. Results are expected in mid 2015.

Dr. Yerxa will present as part of a moderated session titled New Horizons in Drug Delivery, which begins at 8:30am.

Envisia is also pleased to recognize Dr. Adrienne Graves, member of the Envisia Board of Directors, as this year’s recipient of The Catalyst Award. The Catalyst Award is the Glaucoma Research Foundation's highest honor and recognizes exemplary leadership in sustaining innovative glaucoma research and education. Dr. Graves, known for her global commitment to glaucoma research and patient advocacy, will receive the award at the Glaucoma 360 Annual Gala being held on February 5th, 2015 at the Palace Hotel. Envisia is a proud sponsor of this year’s gala and commends Dr. Graves for her outstanding dedication to glaucoma research and awareness.

ABOUT GLAUCOMA RESEARCH FOUNDATION

The Glaucoma Research Foundation is America’s oldest and most experienced nonprofit dedicated solely to vision loss from glaucoma by investing in innovative research, education and support with the ultimate goal of finding a cure. Glaucoma Research Foundation has invested more than $40 million to advance essential research and education programs.

ABOUT ENVISIA THERAPEUTICS™

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, implantable extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.

Contacts

Envisia Therapeutics Media Contact:
Michael Parks, 484-356-7105
michael@pitch360inc.com